Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

August 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
August 10, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
August 4, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
July 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August
July 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
June 22, 2020

Immunic, Inc. to Join Russell 3000® Index
June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Show per page